
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Boston - Data indicate that UV light is increasing the incidence of melanoma development by specifically targeting the Rb pathway. The study is among the first to verify the link between UV exposure and melanoma risk in experimental models.